Publication | Open Access
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
50
Citations
0
References
2022
Year
Breast OncologyMedicinePathologyBreast CancerCancer TreatmentOncologyRadiation OncologyAdjuvant Pertuzumab
No additional data available for this publication yet. Check back later!